Concepedia

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

David L. Paterson, Helmi Sulaiman, Po‐Yu Liu, Mark D. Chatfield, Mesut Yılmaz, Zeti Norfidiyati Salmuna, Mohd Zulfakar Mazlan, Siriluck Anunnatsiri, Rujipas Sirijatuphat, Darunee Chotiprasitsakul,

The Lancet Infectious Diseases · 2025 · 14 citations · 12 references

DOI

Concepts

References

12

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units

Jean‐Louis Vincent, Arnaldo de Mendonça, F. Cantraine et al. · Critical Care Medicine · 1998 · 3.5K citations

, , +12

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Mohsen Naghavi, Kevin S Ikuta, Lucien R Swetschinski et al. · The Lancet · 2024 · 3K citations · Full text

, , +17

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 792 citations

, , +14

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

Patrick N. A. Harris, Paul Anantharajah Tambyah, David Chien Lye et al. · JAMA · 2018 · 770 citations · Full text

, , +16

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

, , +14